Omni Peptides

Reta GLP3

Dhs. 700.00 AED

Sale Sold out

VIAL

Freeze-dried powder in a sealed glass vial. Reconstitute with bacteriostatic water and administer via syringe. The most versatile and cost-effective research format.

RECONSTITUTION & SYRINGE REQUIRED

CARTRIDGE

Pre-filled and ready to administer. Slides into a reusable pen injector — no measuring or mixing required. Clean, discreet, and consistent across research protocols.

REQUIRES COMPATIBLE PEN INJECTOR

NASAL

Delivered via mucosal absorption — no needles required. A popular choice for research protocols where needle-free administration is preferred.

NEEDLE-FREE — SPRAY & GO

PEN

An all-in-one auto-injector with the cartridge pre-loaded. Dial, click, and administer. Optimal for high-frequency research protocols requiring precise, repeatable dosing.

DIAL, CLICK & INJECT — NO PREP

Vials are freeze-dried (lyophilised) powder — kept refrigerated unopened, they remain stable for up to 2 years.

Cartridges, nasal sprays, and pens arrive pre-filled as liquid, must be kept refrigerated at all times, and carry a Beyond Use Date — typically 4–8 weeks from receipt. Please refer to the BUD on the label.

Size 10mg 30mg

Retatrutide (also known as LY3437943) is a synthetic long-acting peptide engineered as a triple agonist of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). This research compound has generated substantial scientific interest for its potential in modulating energy metabolism, appetite regulation, and glucose homeostasis. Preliminary and advanced preclinical studies, along with emerging clinical data, indicate that retatrutide may induce significant weight reduction, improve glycemic control, enhance lipid profiles, and promote liver fat reduction through synergistic activation of these incretin and glucagon pathways. Researchers employ this peptide in laboratory and animal models to investigate mechanisms of obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), and related metabolic disorders. As a research-grade compound, retatrutide is intended exclusively for in vitro and animal studies. Scientists value its balanced potency profile across the three receptors and its utility in advancing understanding of multi-receptor agonism in metabolic regulation.

Molecular Formula

C₂₂₁H₃₄₂N₄₆O₆₈

Molecular Weight

4731.3 g/mol

Sequence

Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-(α-Me-Leu)-Leu-Asp-Lys-[side chain modified Lys]-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂ (Where Aib = 2-aminoisobutyric acid; α-Me-Leu = 2-methylleucine; includes a C20 fatty diacid-γ-Glu-AEEA linker on a lysine residue for extended half-life)

Research Applications

Obesity and Weight Management
Preclinical models demonstrate that retatrutide markedly reduces body weight through decreased food intake, delayed gastric emptying, and increased energy expenditure. Studies show superior efficacy compared to dual agonists, with substantial fat mass loss and preservation of lean mass in various obesity models.
Glycemic Control and Type 2 Diabetes
Retatrutide enhances glucose-dependent insulin secretion, improves insulin sensitivity, and lowers fasting glucose and HbA1c levels in diabetic and prediabetic models. Its triple agonism supports better metabolic outcomes than single or dual incretin therapies.
Liver Health and MASLD/MASH
Investigations reveal potent reductions in liver fat content, improvements in steatosis, and modulation of fibrosis markers. Preclinical and early clinical data highlight its role in reversing metabolic dysfunction-associated steatotic liver disease through combined effects on lipid metabolism and inflammation.
Lipid Metabolism and Cardiovascular Support
Retatrutide favorably alters lipid profiles by reducing triglycerides, LDL, and VLDL while promoting fat oxidation and ketone body production. Research explores its potential benefits in mitigating obesity-related cardiovascular risk factors.
Broader Metabolic and Oncologic Implications
Emerging studies suggest protective effects against obesity-associated cancer progression, with reduced tumor growth and immune reprogramming in preclinical tumor models, potentially linked to sustained weight loss and metabolic improvements.

Storage & Handling

Lyophilised vials are stable at −20°C for up to 2 years unopened. Once reconstituted, refrigerate at 2–8°C and use within 28 days. Avoid repeated freeze-thaw cycles.

Beyond Use Date

Pre-filled formats (cartridge, pen, nasal) carry a beyond-use date of typically 4–8 weeks from receipt. ≥98% purity by HPLC. For in vitro and preclinical research use only — not for human or veterinary use.